BridgeBio Pharma (BBIO) Receivables - Other (2019 - 2024)
BridgeBio Pharma (BBIO) has disclosed Receivables - Other for 6 consecutive years, with $478000.0 as the latest value for Q3 2024.
- Quarterly Receivables - Other fell 85.94% to $478000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $478000.0 through Sep 2024, down 85.94% year-over-year, with the annual reading at $900000.0 for FY2023, 94.73% down from the prior year.
- Receivables - Other hit $478000.0 in Q3 2024 for BridgeBio Pharma, up from $200000.0 in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $100.4 million in Q1 2024 to a low of $200000.0 in Q2 2024.
- Historically, Receivables - Other has averaged $13.9 million across 5 years, with a median of $7.2 million in 2020.
- Biggest five-year swings in Receivables - Other: surged 5220.56% in 2022 and later crashed 96.92% in 2024.
- Year by year, Receivables - Other stood at $8.0 million in 2020, then decreased by 21.25% to $6.3 million in 2021, then skyrocketed by 171.1% to $17.1 million in 2022, then plummeted by 96.49% to $600000.0 in 2023, then fell by 20.33% to $478000.0 in 2024.
- Business Quant data shows Receivables - Other for BBIO at $478000.0 in Q3 2024, $200000.0 in Q2 2024, and $100.4 million in Q1 2024.